The majority of the approved CAR-T cells therapies target CD19, a B-cell-specific antigen that has shown tremendous results in the clinical trials against acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma [5]. The gene discussed is PPIB; the disease is acute lymphoblastic leukemia.